Newly identified CD169+ macrophage subpopulations contribute to antitumor immunity against GBM, facilitating phagocytosis through ligand binding on apoptotic tumor cells and boosting tumor‐specific T‐cell responses through CD169. This evidence concerns the gene SIGLEC1 and neoplasm.